SAN FRANCISCO, CA – (April 8, 2026) – National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) who purchased or otherwise acquired the securities of ImmunityBio between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”) to contact us immediately regarding the pending securities class action against ImmunityBio. The deadline to apply to be lead plaintiff is May 26, 2026.
Class Period: January 19, 2026 – March 24, 2026
Lead Plaintiff Motion Deadline: May 26, 2026
Case information: https://lieffcabraser.com/securities/immunitybio/
Contact us: Email or text investorinfo@lchb.com or call 1-800-541-7358
ImmunityBio, headquartered in San Diego, California, is a biotechnology company. Anktiva, a bladder cancer drug, is the Company’s lead biologic product.
The action alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendant Patrick Soon-Shiong, ImmunityBio’s Executive Chairman and Global Chief Scientific and Medical Officer, materially misrepresented the capabilities of Anktiva; and (2) consequently, Defendants’ statements about ImmunityBio’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On March 24, 2026, the U.S. Food and Drug Administration (“FDA”) published a warning letter it had sent to ImmunityBio’s CEO on March 13, 2026 claiming that Soon-Shiong promoted Anktiva in a false and/or misleading manner in a podcast and television advertisement for Anktiva. The warning letter objected to Soon-Shiong’s claims about Anktiva’s safety, efficacy, and use, including that Anktiva could be used to treat “all cancers” and that it could be used subcutaneously, despite the fact that it was approved only for the treatment of certain bladder cancer and intravesical use. According to the warning letter, the FDA sent letters to an ImmunityBio subsidiary in September 2025 and January 2026 raising similar concerns regarding the Company’s misleading promotion of Anktiva. On this news, the price of ImmunityBio stock fell $1.98 per share, or 21.1%, from its closing price of $9.40 per share on March 23, 2026, to close at $7.42 per share on March 24, 2026, on extremely heavy trading volume.
About Lieff Cabraser
Lieff Cabraser Heimann & Bernstein, LLP, with over 135 attorneys in offices in San Francisco, New York, Nashville, and Munich, Germany, is an internationally-recognized law firm committed to advancing the rights of investors and promoting corporate responsibility. Repeatedly recognized as a “Plaintiffs’ Powerhouse” by Law360, Lieff Cabraser has litigated some of the most important civil cases in the United States, and has assisted clients in recovering over $133 billion in verdicts and settlements. For over 50 years, Lieff Cabraser has remained committed to ensuring access to justice for all.
Source/Contact
Sharon Lee
Lieff Cabraser Heimann & Bernstein, LLP
415 956-1000
slee@lchb.com
Contact us
Use the form below to contact a lawyer at Lieff Cabraser. Please note that our firm does not provide services in the areas of criminal defense, individual landlord-tenant matters, or housing accommodations, and will not respond to inquiries in those areas.
